EYPT EyePoint Pharmaceuticals Inc

$EYPT New starter long in EYPT, a company now trading at a third of its cash after Monday’s 85% wipeout. Quick context for anyone new to the name: EyePoint ran two identical Phase 3s of DURAVYU, a 6 month TKI insert, in wet AMD. LUGANO missed non-inferiority in Aug and took the stock from the mid-teens to the mid-single digits. Monday, LUCIA missed the same primary EP and the stock closed down 85%, $2.99 to $0.44. Same morning, EyePoint announced a 53% workforce cut and an early end to the wet AMD trials to prioritize the DME program, which reads out in Q4 2027. I picked up a starter around $0.41. The math: • ~$118M cash and short-term investments at 9/30 (company estimate, 8-K filed Monday) • ~88.8M economic shares (86.2M common plus 2.6M pre-funded warrants) • ~$1.33 cash per share vs. a $0.45 stock. The market is valuing the company at about a third of its cash • Negative EV of roughly $78M. No funded debt; the ~$22M liability is leases • 12M options outstanding at a $12.75 weighted-avg strike. No comp-plan overhang Why I think it's overdone: • Monday traded ~184M shares, more than twice the share count. Looks like specialist money liquidating, not price discovery • The drug did something. 38% reduction in treatment burden, 52% of eyes supplement-free through week 56, clean safety with redosing. It missed a vision non-inferiority bar. It did not throw a safety signal • DME is a different disease, with an inflammatory component vorolanib also hits through IL-6/JAK1. Phase 2 VERONA showed +7.1 letters and 73% supplement-free vs. 50% for control at week 24 • Both DME Phase 3s are fully enrolled at 551 patients. The hard part is done, and at this price the market is pricing that readout at zero • The cost cut had to happen, and they did it the same day Tell of the tape: RSI is 15 on the daily, 23 on the weekly and about 10 on the 4-hour, with stochastics pinned near zero on all three. That’s a capitulation profile across timeframes. The 50-day at $4.68 doesn’t matter for now. This trades off Monday’s range. Levels I'm watching: • $0.40 -- Monday's low and the 52-wk low. My line for the starter • $0.475 -- today's high • $0.55–$0.60 -- Monday's open and high. A reclaim puts the gap-day shorts offside • $1.00 -- Jefferies' and RBC's new targets, and the Nasdaq listing line Sizing: The cash pile isn’t static. Q3 burned roughly $75M, and Monday’s release dropped the runway guidance that ran in every prior quarter. The Q3 report should show how far $118M stretches and whether a raise comes before the DME data. That’s why this is a starter. I’ll add on strength or on a better-than-feared burn number. If the fundamentals change, I’m out. Bottom line: a third of cash after a binary miss, a fully enrolled Phase 3 in a better-suited indication, and a 53% headcount cut announced day one. The pendulum swung all the way. I’ll take the cheap option. Just sharing my work. Check everything yourself. Not financial advice.

$EYPT Kevin Tang just filed a 13G showing 9.6% of EyePoint. I doubled my position today at $0.37. The filing... • 8,250,200 shares, 9.6%. Initial filing, not an amendment • Event date 10/20/2026, one session after the LUCIA crash. Filed 10/27, on the deadline • Crossing 5% after the crash means at least ~3.9M shares were bought post-readout at sub-$0.50 prices. His Q3 13F, due by Nov 16, shows what he held as of Sept 30 • Passive filing. Not an activist campaign unless a 13D follows Why it matters: Tang is known for buying broken biotechs below cash. His Concentra vehicle has done it repeatedly. When he takes nearly 10% of a stock trading at 27 cents on the dollar, it tells you where he thinks the floor is. The math at $0.36: ~$1.33 cash per share, so the stock trades at 27 cents on the dollar. Tang's stake is worth about $3M on the tape and represents about $11M of company cash. That gap is the trade. Next: Q3 print Nov 4 (est), Tang's 13F by Nov 16, and any 13D. Cash still burns until the cuts take hold, so I'm scaling in. Avg is now around $0.39. I like having Tang on my side of the trade. Again, just sharing my work here. Check everything yourself. NOT financial advice. Partial filing below (first 2 pages only)

$EYPT Sorry but this is a bargain and no brainer for making money ! EyePoint reported cash of $118 million, or $1.36 per share, at the end of the third quarter. the actual stock price is more as 200% under the have cash and 90% of the analysts downgrade the stock price, but not to pennys ! ... the give a rating between $5-8 !!! wake up and buy !!!! the worst unrealistic rating is now by a minimum bid price at $ 1 , but we know one of the new ratings are ever unrealistic .... Most of them give the $5 rating today ... It's a clear buy today on this level !!!! .

$EYPT last night AH we touched $0 48 for the first time and we go over this today... We don't have here a stupid P&D Stock... We have here a Company the have 3 times more cash per share in the pocket right now as the actual stockprice ! And the results wasn't completed failed and the company have enough in the pipeline to go back over $5 ! yesterday, this was a total overreaction ! ... Look to the special Analysts... all of them give a rating between $ 4-8 and these guys knows what she riding ! .

$EYPT ofcourse it was a binary event expected it could have been 15 dollar as well in case for positive results but that's how Biotech works avg down i am having avg of 3.35 will make it around 1 then wait till next year. Don't loose hope stock market can surprise you anytime i am in 90 percent loss but hopeful. In God we trust

$EYPT its not opinion its the fact institutions owning - fact share price .36 fact see it means nothing fact

$EYPT institutions owning this means nothing , only thing that matters is pos is at .37 , 97% down

$EYPT No, the company is not going bankrupt. They have money to spend and they are going to burn it. That is your money they are spending. Based on results to date and the competition, this is quite likely to fail. At that point, investors and the company are looking at bankruptcy. Till then, the executives get a nice paycheck.

$EYPT time to fly kick this short to the moon and let fly this stock to here fair value at a first target to $ 1,32 = cash on hand per share !!!! .

$EYPT investors are shifting to $OTLK to recover their loses… smart money move. $OTLK will launch their fda approved product before 2027, short term to wait. i think a good move is to invest while stock price is under $1

$EYPT I've traded countless biotech crashes like this over the years. The stock is now trading well below its net cash value, even after subtracting debt. And there's still a Phase 3 pipeline, regardless of how things ultimately play out. That alone gives the stock real rebound potential. Today's volume was absolutely insane. I believe most of the people who wanted out have already sold, and there's likely still a massive amount of short interest in play. That's serious fuel for a rebound. Just look at the chart. To me, it's pretty clear the selling is running out of steam. I wouldn't be surprised to see this back above $0.80 within a month.

$EYPT Markets can be irrational. But when you look logically and calmly at Friday's closing price of 0.34 cents, their $118 million cash estimate, plus a phase 3 fully-enrolled pipeline asset, with readouts in 2027 Q4, there is no way this stock doesn't look anything but extremely undervalued here. It appears that Kevin Tang of Tang Capital has also recognised a sharp disconnect in valuation. Apparently, he acquired 8.25 million shares on 20 October, just one day AFTER the failed LUCIA Phase 3 clinical trial results for DURAVYU. Think about that. Why would a sophisticated investor with access to scientific experts and a background with considerable experience in biotechnology buy a significant position if the company had nothing else going for it? Also, keep in mind that about 25% of the outstanding shares are shorted. I'm not promising a squeeze but at some point, at least some of those 21 million shorts will decide to cover. Just sharing my perspective. Good luck to all.

$EYPT looks like Tang bought to shut this down, liquidate and return cash to shareholders. but I'm not sure that strategy has been too successful. mgmt is very entreched and wants their big salaries- and they fight with lots of shenanigans to make this hard to do

$EYPT An unsuccessful Phase 3 trial. The indication being studied now is not as lucrative as wet AMD.

$EYPT What does this person believe to be so optimistic? I'm speechless. The price will soon reach 0.1 cents.

$EYPT the people they buy this stock are delusional, the company had one drug in the pipeline (wet AMD) and it failed the Phase III. so this company has an empty pipeline nothing to work on , and they do not have any products in the market, so the value of this company is zero. better go to a cassino than buying this stock

$EYPT i look at the board, read comments…. Psychology is the key to being a better trader, when i see the comments like, im out, this company is trash… lost too much money… never turning around… it is the mm already knowing your breaking/selling point…. Then you find out sometimes minutes, hours, one day later they sent it, and once again you missed it!! Good luck to all of you wish everyone could make money, but in this game there must be a winner and a loser every time!!

$EYPT Not easily pushing past $1, but $0.40s holding strong as a consolidation level. Looking for a bounce up to $0.60–$0.70

$EYPT this stocks fair value is sitting around 1-1.25$ , this will retrace hard upwards soon

$EYPT things are prety simple here , i mean , if you bought at $14 few months ago or if you bought last week even at $3 and/ or over forget about it its not going back to those prices if you bought first time today or your avg is around .50 you should be fine , they all rebound after huge drop expecially ones with plenty of cash and no debt like eypt imo gl